INTERPACE DIAGNOSTICS CORPORATION

Interpace Diagnostics Corporation specializes in molecular diagnostics and precision medicine solutions, leveraging advanced genomic analysis technologies to support clinical decision-making. Their core capabilities include the development and commercialization of proprietary diagnostic assays, bioinformatics platform integration, and laboratory-developed test (LDT) validation for oncology and other complex diseases. The company applies next-generation sequencing, RNA expression profiling, and biomarker discovery techniques to deliver actionable diagnostic insights to healthcare providers. Key differentiators include their focus on translational research-to-clinical-implementation workflows and proprietary diagnostic platforms designed for high specificity in early disease detection. Technical expertise spans CLIA-certified laboratory operations, regulatory compliance for in vitro diagnostics, and data-driven interpretation systems aligned with CAP and COLA standards. No agency award history is available to define specific government partnerships or contract patterns. Consequently, there is no verifiable record of direct engagements with federal, state, or public health entities. The company operates primarily within the clinical diagnostic services sector, aligned with NAICS 621511, which encompasses medical and diagnostic laboratories. Their market positioning centers on innovation in molecular pathology, with a vertical specialization in cancer diagnostics and personalized medicine applications. They serve the broader healthcare ecosystem by bridging laboratory science with clinical utility, emphasizing evidence-based diagnostic tools for improved patient outcomes. Interpace Diagnostics Corporation is structured as a 2L entity headquartered in Pittsburgh, Pennsylvania. The company holds no federal certifications such as 8(a), HUBZone, or WOSB. While they maintain CLIA and CAP compliance essential for diagnostic laboratory operations, no government-specific certifications are publicly listed. Their geographic presence is concentrated in Pennsylvania, with market positioning focused on private healthcare and clinical research channels rather than federal procurement avenues.